Instrument Inactif

Communiqués CHF Solutions Inc Nasdaq

Actions

US12542Q1022

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Nuwellis Announces Reverse Stock Split	26/06	AQ
Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™	25/06	AQ
Nuwellis and DaVita Extend Supply and Collaboration Agreement Pilot Phase	06/06	AQ
Nuwellis Announces Expansion of Ultrafiltration Program to Pediatric Patients at One of the Largest Hospital Networks in Florida	14/05	AQ
Nuwellis Announces Purchase Agreement with a 50 Hospital Network for Aquadex Ultrafiltration Therapy	09/05	AQ
Nuwellis, Inc. Announces First Quarter 2024 Financial Results	07/05	AQ
Nuwellis Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology	02/05	AQ
Nuwellis Announces Closing of $2.7 Million Public Offering	01/05	AQ
Nuwellis, Inc. To Report First Quarter 2024 Financial Results on May 7, 2024	30/04	AQ
Nuwellis Announces Pricing of $2.7 Million Public Offering	26/04	AQ
Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health	09/04	AQ
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference	07/03	AQ
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results	05/03	AQ
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024	27/02	AQ
Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™	22/02	AQ
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	20/02	AQ
Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference	20/02	AQ
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload	06/02	AQ
Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter	04/01	AQ
New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients	28/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués CHF Solutions Inc Nasdaq

Actions

US12542Q1022

Communiqués

Filtres